
Online Figure 1. Hazard ratios and 95% confidence intervals of HF, CVD, and mortality for classes of longitudinal change in galectin-3

Persistently high levels of Gal-3 were associated with significantly higher risk of incident HF (A), incident CVD (B), and all-cause mortality (C). High-high, low-high, high-low, and low-low represent classes of change in Gal-3 between the earlier exam and the later exam using the clinical cut-off of 17.8 ng/ml. CVD = cardiovascular disease, HF = heart failure, HR (95% CI) = hazard ratio (95% confidence interval).



Online Table 1. Association between change in galectin-3 and

incident outcomes not adjusting for baseline galectin-3 levels

	Change in Gal-3			
Outcome/Model	HR (95% CI)	P-value		
Incident heart failure				
Age, sex- adjusted	1.55 (1.28-1.88)	<0.0001		
Multivariable- adjusted*	1.31 (1.07-1.61)	0.0098		
Incident cardiovascular disease				
		.0.0001		
Age, sex- adjusted	1.34 (1.17-1.55)	< 0.0001		
Multivariable- adjusted*	1.23 (1.06-1.43)	0.0066		
Mortality				
Age, sex- adjusted	1.33 (1.20-1.48)	< 0.0001		
Multivariable- adjusted*	1.20 (1.08-1.35)	0.0012		
	d for age, sex, systolic			

smoking, left ventricular hypertrophy, high-density lipoprotein (HDL) to cholesterol ratio, estimated glomerular filtration rate, prevalent cardiovascular disease (except for CVD model). Mortality was further adjusted for prevalent heart failure.

†Hazard ratio and 95% confidence intervals for 1 standard deviation

(SD) increase in log-Gal3 levels over a 10-year period. This

corresponds to 3.3 ng/ml change in Gal-3.

Outcome/Model (Events/At risk)	HR (95% CI) †	P-value	
Incident heart failure (108/2417)			
Age, sex, baseline Gal-3- adjusted	1.55 (1.29 - 1.87)	< 0.0001	
Multivariable- adjusted*	1.35 (1.10 - 1.67)	0.004	
Incident cardiovascular disease (213/2268)			
Age, sex, baseline Gal-3- adjusted	1.39 (1.21 - 1.60)	< 0.0001	
Multivariable- adjusted*	1.28 (1.10 - 1.49)	0.001	
Mortality (342/2456)			
Age, sex, baseline Gal-3- adjusted	1.34 (1.21 - 1.48)	< 0.0001	
Multivariable- adjusted*	1.29 (1.15 - 1.44)	< 0.0001	

Online Table 2. Association between longitudinal change in galectin-3 and incident outcomes after further adjusting for baseline BNP

*Multivariable models are adjusted for baseline galectin-3 levels, age, sex, systolic blood pressure, antihypertensive treatment, diabetes, body mass index, smoking, left ventricular hypertrophy, highdensity lipoprotein (HDL) to cholesterol ratio, estimated glomerular filtration rate, prevalent cardiovascular disease (except for CVD model) as well as brain natriuretic peptide (BNP). Mortality was further adjusted for prevalent heart failure.

[†]Hazard ratio and 95% confidence intervals for 1 standard deviation (SD) increase in log-Gal3 levels over a 10-year period. This corresponds to 3.3 ng/ml change in Gal-3.

	Heart failu	re	Cardiovascular o	lisease	Mortality	
Quartile	(108 events)		(213 events)		(348 events)	
	HR (95% CI)*	P-value	HR (95% CI)*	P-value	HR (95% CI)*	P-value
Quartile 1	Referent		Referent		Referent	
Quartile 2	1.23 (0.61-2.50)	0.56	1.29 (0.83-2.01)	0.25	1.02 (0.70-1.47)	0.92
Quartile 3	1.49 (0.75-2.93)	0.25	1.23 (0.79-1.91)	0.37	1.19 (0.84-1.70)	0.33
Quartile 4	1.91 (0.97-3.76)	0.06	1.74 (1.12-2.71)	0.01	1.94 (1.37-2.73)	0.0002
P for trend		0.04		0.02		< 0.0001

Online Table 3. Association between quartiles of longitudinal change in galectin-3 and clinical outcomes

*HR (95%CI) represents hazard ratio (95% confidence interval) using a multivariable-adjusted model adjusting for baseline galectin-3 levels, age, sex, systolic blood pressure, antihypertensive treatment, diabetes, body mass index, smoking, left ventricular hypertrophy, high-density lipoprotein (HDL) to cholesterol ratio, estimated glomerular filtration rate, prevalent cardiovascular disease (except for CVD model). Mortality was further adjusted for prevalent heart failure.

	Heart failure		Cardiovascular disease		Mortality	
	HR (95% CI)*	P- value	HR (95% CI)*	P- value	HR (95% CI)*	P- value
High-High	2.28 (1.28-4.05)	0.0005	1.80 (1.13-2.86)	0.01	2.25 (1.61-3.15)	< 0.0001
Low -High	1.82 (1.03-3.22)	0.04	1.43 (0.89-2.28)	0.13	1.76 (1.25-2.48)	0.0012
High-Low	0.47 (0.15-1.51)	0.20	0.86 (0.47-1.57)	0.62	1.01 (0.63-1.60)	0.97
Low-Low	Referent		Referent		Referent	

Online Table 4. Association between classes of longitudinal change in galectin-3 and clinical outcomes

*HR (95%CI) represents hazard ratio (95% confidence interval) for categories of trend as compared to reference level of low-low using a multivariable-adjusted model adjusting for baseline galectin-3 levels, age, sex, systolic blood pressure, antihypertensive treatment, diabetes, body mass index, smoking, left ventricular hypertrophy, high-density lipoprotein (HDL) to cholesterol ratio, estimated glomerular filtration rate, prevalent cardiovascular disease (except for CVD model). Mortality was further adjusted for prevalent heart failure.

High-high, low-high, high-low, and low-low represent classes of change in Gal-3 between the earlier exam and the later exam using the clinical cut-off of 17.8 ng/ml.